Corbus Pharmaceuticals to Attend 2024 RBC Healthcare Conference

28 June 2024

NORWOOD, Mass., May 09, 2024 - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company") has announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will be actively participating in the 2024 RBC Capital Markets Global Healthcare Conference. This event is scheduled to take place in New York, NY on May 14-15, 2024. Dr. Cohen will engage in a fireside chat and hold one-on-one meetings with investors at the conference. The fireside chat is set for Tuesday, May 14, 2024, at 9:30 a.m. ET, and will be available via webcast.

Corbus Pharmaceuticals Holdings, Inc. is a precision oncology company with a diverse portfolio aimed at addressing serious illnesses through innovative scientific approaches. Their pipeline includes several promising drug candidates: CRB-701, CRB-601, and CRB-913. 

CRB-701 is an advanced antibody-drug conjugate designed to target Nectin-4 expression on cancer cells, delivering a cytotoxic payload directly to the tumor. This targeted approach aims to minimize damage to healthy cells and improve the efficacy of cancer treatment.

CRB-601 is an anti-integrin monoclonal antibody which blocks the activation of TGFβ that is expressed on cancer cells. By inhibiting TGFβ, CRB-601 is intended to prevent the growth and spread of cancer cells, offering a potential new therapy for various cancers.

CRB-913 is a highly peripherally restricted CB1 receptor inverse agonist developed for the treatment of obesity. By targeting the CB1 receptor, CRB-913 aims to regulate appetite and energy balance, providing a new approach to managing obesity.

Corbus Pharmaceuticals is headquartered in Norwood, Massachusetts, and remains committed to leveraging its scientific expertise to develop innovative therapies for conditions with significant unmet needs. The company continues to focus on exploring well-understood biological pathways to deliver cutting-edge treatments.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!